

Bulletin – Changes to CCSD Schedule of Diagnostic Tests**Issue Number:** 092**Date:** 13/06/2024, **updated 17/06/24**

The CCSD Working Group has reviewed requests since the last cut-off date of 3rd May 2024 and has agreed on the following changes to the CCSD Diagnostic Schedule with a **recommended adoption date of the 8th of August 2024**. There is nothing to stop these codes being implemented before that date.

Previous version of this issue stated that request 6801 should have a new code of 0052G. This was incorrect and the new code is 0056G, with an updated request number of 7178 (highlighted in red in the table below).

All other information in this bulletin remains unchanged.

New code(s)

Request	Code	Approved Narrative
6780	0593U	Plasma Guanidinoacetate (GUAP) Urine
6795	3030G	Circulating tumour DNA profile (Guardant360)
7178	0056G	ClonoSEQ
6802	7132U	Schistosoma - Urine (Urch)
6803	1788U	C-peptide level - Urine
6804	3031G	Digistain
6805	3032G	HER2DX

Inactivation(s)

Request	Code	Approved Narrative
6796	3100G	Circulating tumour DNA profile for breast cancer (Guardant 360)
6797	3101G	Circulating tumour DNA profile for upper gastro-intestinal cancer (Guardant 360)
6798	3102G	Circulating tumour DNA profile for colo-rectal cancer (Guardant 360)
6799	3103G	Circulating tumour DNA profile for cancer of unknown primary (Guardant 360)
6800	3104G	Circulating tumour DNA profile for lung cancer (Guardant 360)

Please note that the inclusion of diagnostic codes within the CCSD Schedule does not indicate the automatic agreement of individual insurers to provide benefit for this procedure. Please contact each insurer directly to ascertain whether benefit is provided.